▲ Peaking
Business
EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.
EyePoint shares experience a sharp decline following the release of pivotal data regarding the company's primary drug candidate.
1 trends tracked about this subject — the full history, oldest to newest below.
EyePoint shares experience a sharp decline following the release of pivotal data regarding the company's primary drug candidate.